Our manifesto for cancer drug discovery and development – focusing on innovation to tackle treatment resistance and meeting patients’ needs 30 Apr 2019 Professor Paul Workman argues that concerted action is needed to accelerate patients’ access to today’s new treatments – and incentivise creation of the innovative new medicines of tomorrow that will lead to step changes in clinical outcome. Find out more Show/Hide
Why regulators must move with the science if we’re to get innovative new treatments to patients more quickly 05 Dec 2018 Our CEO, Professor Paul Workman, discusses the findings of the ICR's new drug access report, which asks how we can best harness advances in science to bring innovative drugs to patients. Find out more Show/Hide